KITE PHARMA INC's ticker is KITE and the CUSIP is 49803L109. A total of 62 filers reported holding KITE PHARMA INC in Q3 2014. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $25,699,000 | +69.8% | 142,922 | -2.1% | 0.02% | +63.6% |
| Q2 2017 | $15,136,000 | +51.4% | 146,003 | +14.7% | 0.01% | +57.1% |
| Q1 2017 | $9,995,000 | +61.8% | 127,338 | -7.6% | 0.01% | +40.0% |
| Q4 2016 | $6,177,000 | -30.3% | 137,758 | -13.2% | 0.01% | -16.7% |
| Q3 2016 | $8,866,000 | +5.8% | 158,710 | -5.3% | 0.01% | 0.0% |
| Q2 2016 | $8,383,000 | +15.5% | 167,651 | +6.0% | 0.01% | 0.0% |
| Q1 2016 | $7,259,000 | -25.1% | 158,118 | +0.6% | 0.01% | -14.3% |
| Q4 2015 | $9,690,000 | +5.2% | 157,253 | -4.9% | 0.01% | 0.0% |
| Q3 2015 | $9,211,000 | +18.1% | 165,428 | +29.3% | 0.01% | +16.7% |
| Q2 2015 | $7,798,000 | +111.9% | 127,905 | +100.5% | 0.01% | +100.0% |
| Q1 2015 | $3,680,000 | +113.0% | 63,793 | +112.9% | 0.00% | +200.0% |
| Q4 2014 | $1,728,000 | +126.8% | 29,969 | +12.1% | 0.00% | 0.0% |
| Q3 2014 | $762,000 | – | 26,731 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wildcat Capital Management, LLC | 2,358,084 | $108,260,000 | 37.66% |
| Coastal Bridge Advisors, LLC | 250,040 | $11,479,000 | 8.02% |
| RTW INVESTMENTS, LP | 343,503 | $15,770,000 | 5.72% |
| DSAM Partners (London) Ltd | 256,550 | $11,778,000 | 5.26% |
| Silver Rock Financial LLC | 109,199 | $5,013,000 | 5.09% |
| Casdin Capital, LLC | 75,000 | $3,443,000 | 3.95% |
| EcoR1 Capital, LLC | 150,000 | $6,887,000 | 2.41% |
| Vivo Capital, LLC | 193,193 | $8,869,000 | 2.22% |
| BB BIOTECH AG | 750,000 | $34,433,000 | 1.37% |
| MENORA MIVTACHIM HOLDINGS LTD. | 494,988 | $22,725,000 | 1.36% |